Stock Groups

Gilead Earnings, Revenue Beat in Q3 -Breaking

by Mike Robinson

[ad_1]

© Reuters. Gilead Beats Revenue in Q3

Gilead (NASDAQ 🙂 announced Thursday that the third quarter beat analyst forecasts with revenue surpassing expectations.

Gilead posted earnings per share (EPS) of $2.65 on revenues of $7.42B. Investing.com polled analyst to predict EPS at $1.74 for revenue $6.25B.

Gilead shares have risen 15% since the start of the year but are still 8.21% below the $73.34 high it reached on August 18. The Gilead shares are performing poorly compared to the, which has risen 22.42% since the beginning of the year.

Following the report, Gilead shares fell by 3.07% after hours trade.

Gilead’s earnings are in line with other top Healthcare sectors this month

Gilead’s report follows an earnings beat by J&J on October 19, who reported EPS of $2.6 on revenue of $23.34B, compared to forecasts EPS of $2.35 on revenue of $23.64B.

Thermo Fisher Scientific beat all expectations Wednesday, posting a third quarter EPS (EPS) of $5.76 on revenues of $9.33B compared with EPS forecasted at $4.68 for revenue of $8.33B.

Keep up to date with all the earnings reports coming soon by visiting Investing.com’s earnings calendar

Disclaimer Fusion MediaThis website does not provide accurate and current data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media does not accept any liability for trade losses you may incur due to the use of these data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.



[ad_2]